Cellectis S.A. - CLLS Revenue Dynamics YoY (Last Twelve Months)

Graphic logo of cellectis.com (CLLS)

The year-over-year percentage change in sales volume for the LTM on the GURU.Markets terminal analytical chart illustrates revenue dynamics, where the -0.10 level indicates the parameter's status. Cellectis S.A. (CLLS) minimizes production outsourcing through its own capacities, although it relies on external researchers. Amidst fierce patent battles and a lack of stable assets, the company's financial health depends entirely on the outcomes of current clinical trials.

Cellectis (CLLS): Sales Growth YoY (TTM) from 02/11/2024 to 11/16/2026

Cellectis (CLLS) - metric breakdowns and financial figures

- stock price and consensus target price:
- issuer market value details:
Fundamental company valuation:Cellectis SA
Flagship merchandise of cellectis.com

Fundamental asset selection requires an analysis of revenue dynamics to identify the business expansion phase by comparing current and prior periods. The -0.10 metric measures the percentage change in sales volume over the last twelve months, which for the allogeneic CAR-T therapy pioneer Cellectis S.A. (CLLS) reflects the commercialization pace of "off-the-shelf" drugs, as indicated by this TTM annual sales growth chart.